Align Technology, Inc.

LSE:0HCK Stock Report

Market Cap: US$16.9b

Align Technology Valuation

Is 0HCK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HCK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0HCK ($222) is trading below our estimate of fair value ($319.23)

Significantly Below Fair Value: 0HCK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HCK?

Key metric: As 0HCK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0HCK. This is calculated by dividing 0HCK's market cap by their current earnings.
What is 0HCK's PE Ratio?
PE Ratio38.2x
EarningsUS$441.57m
Market CapUS$16.86b

Price to Earnings Ratio vs Peers

How does 0HCK's PE Ratio compare to its peers?

The above table shows the PE ratio for 0HCK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37x
CTEC ConvaTec Group
39.5x20.5%UK£4.8b
AMS Advanced Medical Solutions Group
41x23.0%UK£456.3m
SN. Smith & Nephew
35.4x22.5%UK£8.6b
TSTL Tristel
32.3x17.5%UK£209.8m
0HCK Align Technology
38.2x17.5%US$16.9b

Price-To-Earnings vs Peers: 0HCK is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the peer average (37x).

Price to Earnings Ratio vs Industry

How does 0HCK's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0HCK 38.2xIndustry Avg. 29.5xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0HCK is expensive based on its Price-To-Earnings Ratio (38.2x) compared to the European Medical Equipment industry average (29.5x).

Price to Earnings Ratio vs Fair Ratio

What is 0HCK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HCK PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio38.2x
Fair PE Ratio44.6x

Price-To-Earnings vs Fair Ratio: 0HCK is good value based on its Price-To-Earnings Ratio (38.2x) compared to the estimated Fair Price-To-Earnings Ratio (44.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HCK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$222.00
US$261.24
+17.7%
12.1%US$320.00US$200.00n/a13
Nov ’25US$208.08
US$261.24
+25.5%
12.1%US$320.00US$200.00n/a13
Oct ’25US$247.42
US$287.01
+16.0%
14.1%US$350.00US$215.00n/a13
Sep ’25US$236.35
US$287.01
+21.4%
14.1%US$350.00US$215.00n/a13
Aug ’25US$228.66
US$299.69
+31.1%
13.6%US$353.99US$215.00n/a13
Jul ’25US$243.29
US$333.43
+37.0%
11.8%US$400.00US$250.00n/a14
Jun ’25US$253.95
US$341.64
+34.5%
11.7%US$400.00US$250.00n/a14
May ’25US$280.62
US$336.55
+19.9%
12.0%US$400.00US$250.00n/a15
Apr ’25US$328.12
US$310.15
-5.5%
13.4%US$355.00US$215.00n/a15
Mar ’25US$304.29
US$309.14
+1.6%
13.0%US$350.00US$215.00n/a15
Feb ’25US$277.81
US$308.36
+11.0%
13.3%US$344.00US$215.00n/a14
Jan ’25US$275.92
US$277.58
+0.6%
19.9%US$344.00US$180.00n/a14
Dec ’24US$223.40
US$278.36
+24.6%
19.7%US$378.00US$180.00n/a14
Nov ’24US$180.97
US$278.36
+53.8%
19.7%US$378.00US$180.00US$208.0814
Oct ’24US$309.19
US$393.31
+27.2%
11.7%US$450.00US$270.00US$247.4213
Sep ’24US$374.26
US$393.31
+5.1%
11.7%US$450.00US$270.00US$236.3513
Aug ’24US$379.14
US$385.25
+1.6%
11.2%US$440.00US$270.00US$228.6612
Jul ’24US$353.74
US$354.91
+0.3%
13.9%US$420.00US$225.00US$243.2911
Jun ’24US$294.76
US$354.91
+20.4%
13.9%US$420.00US$225.00US$253.9511
May ’24US$322.40
US$354.91
+10.1%
13.9%US$420.00US$225.00US$280.6211
Apr ’24US$327.81
US$334.27
+2.0%
16.7%US$420.00US$190.00US$328.1211
Mar ’24US$308.82
US$333.70
+8.1%
17.5%US$420.00US$190.00US$304.2910
Feb ’24US$273.07
US$241.00
-11.7%
20.5%US$314.00US$160.00US$277.8110
Jan ’24US$206.97
US$250.00
+20.8%
25.9%US$375.00US$160.00US$275.9211
Dec ’23US$199.86
US$250.00
+25.1%
25.9%US$375.00US$160.00US$223.4011
Nov ’23US$195.36
US$241.90
+23.8%
25.8%US$375.00US$160.00US$180.9710

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$401.70

7D

-0.06%

1Y

-16.0%

Centene

US$30.5b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

0HVB

US$60.47

7D

5.2%

1Y

-18.4%

Kooth

UK£60.0m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.65

7D

1.5%

1Y

-45.2%